2Press MF,Bernstein L,Thomas PA,et al.HER-2/neu gene amplification characterized by fluorescence in situ hybridization:poor prognosis in node-negative breast carcinomas.J Clin Oncol,1997,15:2894-2904.
3Ratclitte N,Wells W,Wheeler K,et al.The combination of in situ hybridization and immunohistochemical analysis:an evaluation of HER-2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium.Mod Pathol,1997,10:1247-1252.
4Tanner M,Gancberg D,DiLeo A,et al.Chromogenic in situ hybridization:a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.Am J Pathol,2000,157:1467-1472.
5Zhao JX,Wu R,Au A,et al.Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.Mod Pathol,2002,15:657-665.
6Gupta D,Middleton LP,Whitaker MJ,et al.Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in braest cancer.Am J Clin Pathol,2003,119:381-387.
7Williams SJ, Wreschner DH, Tran M, et al. MUC13: a novel human cell surface mucin expressed by epithelial and hemopoietic cell [J].J Biol Chem, 2001, 276(21):18327～18336.
1Kaufmann M,Von Minckwitz G, Mamounas E, et al. Rec- ommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant SystemicTherapy in Primary Breast Cancer[J]. Annals of surgical oncology,2012,19(5) ..1508-1516.
2Pogue.-Geile KL, Kim C, JeongJ H, et al. Predicting De- gree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31 [J]. Journal of the National Cancer Institu- te,2013,105(23) ..1782-1788.
3Guarneri V,Broglio K,Kau S,et al. Prognostic value of pathologic complete response after primary chemother- apy in relation to hormone receptor status and other factors [J]. Journal of Clinical Oncology, 2006,24 (7) : 1037-1044.
4ASlamon D,Clark G,Wong S,et al. Human breast cancer.. correlation of relapse and survival with amplification of the HER-2/neu oncogene [J]. Science, 1987,235 (4785) : t77- I82.
5Baselga J, Bradbury I, Eidtmann H, et al. , Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO) : a randoraised, open-label, mul- ticentre, phase 3 trial[J]. The Lancet, 2012, 379 (9816) : 633-640.
6Kim MM, Allen P, Gonzalez-AnguloAM, et al. Patho- logic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer[J]. Annals of Oncology,2013,24(8) : 1999-2004.
7Jones RL, Salter J, Hern RA, et al, Relationship be- tween oestrogen receptor status and proliferation in predicting response and long-term outcome to neoad- juvant chemotherapy for breast cancer [J]. Breast cancer research and treatment, 2010, 119 (2): 315- 323.
